Bristol Myers (BMY) delivered an impressive performance in the past month after being under pressure for quite some time. The ...

Dispatch Bio launched with $216 million – backed primarily by Parker Institute for Cancer Immunotherapy, founded by entrepreneur Sean Parker, and ARCH Venture Partners. SAB BIO announced an ...

Bristol Myers Squibb (BMY) is pushing for Reblozyl’s label expansion despite tough competition and generic pressures.

Vertex Pharmaceuticals received a boost with Canada's approval of ALYFTREK for cystic fibrosis. This approval boosts sentiment. The stock saw a 7% rise over the past month amid broader market optimism ...